|
METHODOLOGY ISSUES |
PMI1 |
FROM
HEALTH-RELATED QOL TO UTILITY - IS THERE A WAY?
Svensson K1, Szende A2, Ståhl E1, Lundbäck B3, 1AstraZeneca R&D
Lund, Sweden, Lund, Sweden; 2Medtap International, Jisp, Netherlands;
3University Hospital, Umeå, Sweden |
| PMI2 |
ESTIMATING
PREVALENCE AND SURVIVAL BY STAGE OF CANCER FROM THE US SEER DATABASE:
COLORECTAL CANCER
Koo LC1, Lally CA2, 1AstraZeneca, Wilmington, DE, USA; 2Emory
University, Atlanta, GA, USA |
| PMI3 |
DEVELOPMENT OF
DESCRIPTIONS OF TREATMENTS FOR COLORECTAL CANCER FOR USE IN PREFERENCE
MEASUREMENT
Wild D1, Grove A1, Hakim Z2, Kind P3, 1Oxford Outcomes, Headington,
Oxford, UK; 2Roche Pharmaceuticals, Nutley, NJ, USA; 3University of York,
Heslington, York, UK |
| PMI4 |
ASSESSING
RESOURCE USE WITHIN ONCOLOGY INDICATIONS: A METHODOLOGICAL APPROACH TO
CONDUCTING RETROSPECTIVE DATA ANALYSES
Semroc G1, Tierce J2, Stolshek B3, 1Epinomics Research, Inc, San
Diego, CA, USA; 2Epinomics Research, Inc, Alexandria, VA, USA; 3Amgen,
Thousand Oaks, CA, USA |
| PMI5 |
FACTORS FOR THE
VARIATION IN THE PREVALENCE OF ARTERIAL PERIPHRIAL DISEASE – STUDY
IMPLICATIONS FOR OUTCOMES RESEARCH
Wang AY, Pfizer Inc, Ann Arbor, MI, USA |
| PMI6 |
ESTIMATING THE
BENEFITS OF ANTIHYPERTENSIVE THERAPY: AN ASSESSMENT OF PULSE PRESSURE
Grover SA1, Brewer C1, Coupal L1, Zowall H1, Pradhan AA2, 1McGill
University, Montreal, QC, Canada; 2Bristol-Myers Squibb Pharmaceuticals
Group, Montreal, QC, Canada |
| PMI7 |
MODELING ON THE
STOCHASTIC FRONTIER: COST OF TREATMENT FOR ACUTE DECOMPENSATED HEART
FAILURE
de Lissovoy G1, Stier DM2, Ciesla G1, Strausser B3, Burger AJ4,
1MEDTAP International, Bethesda, MD, USA; 2Eureka Research Inc, San
Francisco, CA, USA; 3Scios Inc, Sunnyvale, CA, USA; 4Beth Israel
Deaconess Medical Center, Boston, MA, USA |
| PMI8 |
VALIDATION OF
COST ESTIMATION TECHNIQUE FOR HOSPITALIZATIONS FOR USE IN MULTINATIONAL
ECONOMIC EVALUATIONS
Reed SD1, Friedman JY1, Gnanasakthy A2, Schulman KA1, 1Duke
Clinical Research Institute, Durham, NC, USA; 2Novartis Pharmaceutical
Corp, East Hanover, NJ, USA |
| PMI9 |
THE RELATIONSHIP
BETWEEN DISEASE AREA AND TYPE OF ECONOMIC STUDY – DOES IT EXIST?
Richard L, Heron Evidence Development Ltd, Stevenage,
Hertfordshire, UK |
| PMI10 |
DANCING WITH THE
DEVIL: THE IMPORTANCE OF SUB-GROUP ANALYSIS IN ECONOMIC EVALUATION
Briggs AH1, Glick H2, Hoch J3, Willan AR4, 1University of Oxford,
Oxford, UK; 2University of Pennsylvania, Philadelphia, PA, USA;
3University of Western Ontario, London, ON, Canada; 4McMaster University,
Hamilton, ON, Canada |
| PMI11 |
LIFE YEARS LOST
DUE TO CHD
Wendland G1, Lauterbach K2, 1Guido Wendland, Cologne, NW,
Germany; 2University of Cologne, Cologne, Germany |
| PMI12 |
DEVELOPMENT OF A
NUTRITION QUALITY OF LIFE MEASURE
Schumacher G, Barr J, Northeastern University, Boston, MA, USA |
| PMI13 |
STANDARD GAMBLE
AND CONJOINT UTILITY WEIGHTS: VALIDITY, FEASIBILITY, AND USEFULNESS
Johnson FR1, Mauskopf J1, Hauber AB2, 1Research Triangle
Institute, Research Triangle Park, NC, USA; 2Parametric Research
Corporation, Hatboro, PA, USA |
| PMI14 |
THE DEVELOPMENT
OF A SEVERITY STAGING SYSTEM FOR ECONOMIC EVALUATIONS OF THE PROGRESSION
OF GLAUCOMA
Walt JG1, Evans SJ2, Doyle JJ2, Casciano J2, 1Allergan, Irvine,
CA, USA; 2The Analytica Group, New York, NY, USA |
| PMI15 |
MATHEMATICAL
MODEL (MM) OF ANTIBIOTIC (AB) IN VITRO SUSCEPTIBILITY (SUS) OVER THE
COMPLETE RANGE OF MINIMUM INHIBITORY CONCENTRATION (MIC)
Chambers RB, Pankey GA, Ochsner Clinic Foundation, New Orleans,
LA, USA |
| PMI16 |
USE OF VARIOUS
METHODS FOR COST ESTIMATION IN MULTI-NATIONAL ECONOMIC EVALUATIONS
Constenla DO, Pan-American Health Organization/World Health
Organization (PAHO/WHO), Santiago, Chile |
| PMI17 |
METHODS FOR
ASSESSING THE VALUE OF ANTIPSYCHOTIC TREATMENT: A NEW PERSPECTIVE FOR
INTERPRETING SERVICE UTILIZATION
Tunis SL1, Ascher-Svanum H1, Browne RA1, Wang FP1, Kinon BJ2, 1Eli
Lilly and Company, Indianapolis, IN, USA; 2Lilly Research Laboratories,
Indianapolis, IN, USA |
| PMI18 |
PERFORMING
EPIDEMIOLOGICAL STUDIES IN SCHIZOPHRENIA:
A PROPENSITY SCORE MODEL TO PREDICT SELECTION OF ATYPICAL ANTIPSYCHOTIC
Irish W1, Neighbors D1, Grogg A2, Lopez R1, Girts T2, Degen K3,
1RTI Health Solutions, Research Triangle Park, NC, USA; 2Janssen
Pharmaceutica, Titusville, NJ, USA; 3Middlesex Hospital, Middletown, CT,
USA |
| PMI19 |
THE USE OF
PHARMACY CLAIMS DATA TO EVALUATE QUALITY OF PHARMACOLOGIC CARE FOR
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Hankin C1, Pierson P2, Cooper D2, Wright A2, 1McNeil Consumer and
Specialty Pharmaceuticals, Fort Washington, PA, USA; 2Advance PCS, Hunt
Valley, MD, USA |
| PMI20 |
TRENDS IN
PEDIATRIC HEALTH ECONOMIC EVALUATION: 1980 TO 1999
Ungar WJ, The Hospital for Sick Children Research Institute,
Toronto, ON, Canada |
| PMI21 |
EVALUATING HEALTH
PLAN MANAGEMENT OF EMPLOYER INDIRECT COSTS: METHODOLOGICAL ISSUES
Ricci J, Chee E, Matousek DM, AdvancePCS, Center for Work and
Health, Hunt Valley, MD, USA |
| PMI22 |
ITEM REDUCTION OF
A NEW PHARMACEUTICAL THERAPY RELATED QUALITY OF LIFE (PTRQOL) INSTRUMENT:
FACTOR ANALYSIS METHOD OR CLINICAL IMPACT METHOD?
Sankaranarayanan J, Bhor M, Murawski MM, Purdue University, West
Lafayette, IN, USA |
| PMI23 |
THE ODDS OF
BENEFIT VERSUS NON-BENEFIT OF THERAPY ASSOCIATED WITH THE NUMBER NEEDED
TO TREAT
Kamae I1, Aino H1, Yanagisawa S1, Nishimura K2, 1Kobe University,
Kobe, Japan; 2Harvard University, Boston, MA, USA |
| PMI24 |
JUSTIFYING THE
USE OF COST MINIMIZATION ANALYSIS: DEMONSTRATION OF COMPARATOR
EQUIVALENCE
Bennett HA1, Bonari L1, Howard L1, Lee A2, Ljungberg C1, Schoedel
K1, Einarson T1, 1University of Toronto, Toronto, ON, Canada; 2The
Hospital for Sick Children Research Institute, Toronto, ON, Canada |
| PMI25 |
THE STATUS OF
QUALITY OF LIFE DATA IN HEALTH TECHNOLOGY ASSESSMENTS : EVIDENCE FROM
PUBLISHED NICE APPRAISALS
Kind P, Outcomes Research Group, York, UK |
| PMI26 |
FEATURES OF
GOMPERTZ FUNCTIONS IN MODELING MORTALITY RATES
Wendland G1, Lauterbach K2, 1Guido Wendland, Cologne, NW,
Germany; 2University of Cologne, Cologne, Germany |
| PMI27 |
A UTILITY-MAXIMISATION
MODEL OF CHOICE BETWEEN MEDICAL INTERVENTIONS INVOLVING RISK
Walshe R, University of Cologne, Cologne, Germany |
| PMI28 |
ELECTRONIC DATA
COLLECTION OF PATIENT-REPORTED OUTCOMES
Schmier JK1, Rentz AM1, Dennison CR1, Jones R2, Rothman M2,
1MEDTAP International, Inc, Bethesda, MD, USA; 2Health
Economics, Johnson & Johnson, Raritan, NJ, USA |
| PMI29 |
PATIENT-GENERATED
OUTCOMES: FAD OR HERE TO STAY?
Patel KK, Veenstra DL, University of Washington, Seattle, WA, USA |
| PMI30 |
A TWO-DIMENSIONAL
MARKOV MODEL WITH DIFFERENT CYCLE LENGTHS FOR A CHRONIC CONDITION WITH
SLOW IRREVERSIBLE DISEASE PROGRESSION AND RECURRENT PERIODS OF SEVERE
SYMPTOMS
Borg S, Ericsson Å, AstraZeneca R&D Lund, Lund, Sweden |
| PMI31 |
PSYCHOMETRIC
PROPERTIES OF THE HEALTH RELATED QUALITY OF LIFE INSTRUMENT IN THE
MEDICAL EXPENDITURE PANEL SURVEY
Shetty VL, Crawford SY, Conrad KJ, Lambert BL, Woodward J,
University of Illinois at Chicago, Chicago, IL, USA |
| PMI32 |
EVALUATING THE
USE OF PROBABILISTIC SENSITIVITY ANALYSIS VIA MONTE CARLO SIMULATION
(MCS): AN AUDIT OF THE HEALTH ECONOMIC LITERATURE
Botteman M, Bell C, Stephens J, Abt Associates Clinical Trials,
Bethesda, MD, USA |
| PMI33 |
LITERATURE REVIEW
OF GUIDELINES FOR CROSS-CULTURAL ADAPTATION OF HRQL MEASURES: UPDATED
RESULTS
Conway K, Mear I, Acquadro C, Mapi Research Institute, Lyon,
France |
| PMI34 |
A LOGICAL PROBLEM
IN VIEWING UTILITY THEORY AS NORMATIVE
Gagnon DD, Johnson & Johnson Pharmaceutical Research and
Development, L.L.C, Raritan, NJ, USA |
| PMI35 |
WITHDRAWN |
| PMI36 |
INCORPORATING
JAPAN INTO GLOBAL OUTCOMES RESEARCH PROTOCOLS
Doherty J, Pharmacia Inc, Tokyo, Japan |
| PMI37 |
INTEGRATION OF
INTERNATIONAL INPUT INTO INSTRUMENT DESIGN: TRANSLATABILITY ASSESSEMENT
Conway K, Mear I, Mapi Research Institute, Lyon, France |
| PMI38 |
EVALUATING THE
STRUCTURE OF PHARMACOECONOMIC FELLOWSHIP PROGRAMS
Maio V, Lofland JH, Crawford AG, Thomas Jefferson University,
Philadelphia, PA, USA |
| PMI39 |
THE USE OF DRG-RELATED
DATA ON KNEE PROCEDURES IN THE ANALYSIS OF UTILISATION OF RESOURCES
BETWEEN BELGIAN HOSPITALS
Putman K1, Corens D1, Nieberding P2, Schots J2, Beeckmans J3,
1Centre of Health Economics and Hospital Policy - Vrije Universiteit
Brussel, Brussel, Belgium; 2University Hospital - Vrije Universiteit
Brussel, Brussel, Belgium; 3Centre of Health Economics and Hospital
Policy - University Hospital, Vrije Universiteit Brussel, Brussel,
Belgium |
| PMI40 |
THE POTENTIAL
IMPORTANCE OF DATA SOURCES AND ANALYTIC APPROACHES TO THE EXTERNAL
VALIDITY OF ECONOMIC STUDIES
Chumney ECG, Simpson KN, Medical University of South Carolina,
Charleston, SC, USA |
| PMI41 |
SATISFACTION WITH
SMOKING CESSATION TREATMENTS –
A SYSTEMATIC REVIEW OF THE DIMENSIONS
Holdford DA, Virginia Commonwealth University, Richmond,
VA, USA |
| PMI42 |
DESIGN AND
VALIDITY OF AUTOMATED HEALTH CARE DATA SCREENS TO DETECT IN-HOSPITAL
ADVERSE DRUG EVENTS
Sauer BC, Winterstein AG, Mattenklotz AM, University of Florida,
Gainesville, FL, USA |
|
MENTAL HEALTH (including Alzheimer’s Disease,
Dementia, Alcoholism, and Attention Deficit Disorder) |
|
Clinical Outcomes
Presentations |
| PMH1 |
USEFULNESS OF
ELECTRONIC COMPLIANCE DATA IN AN EFFECTIVENESS TRIAL
Cramer J1, Rosenheck R1, Krystal J1, Kirk G2, Krol W2, 1Yale
University School of Medicine, West Haven, CT, USA; 2Dept. of Veterans
Affairs, Perry Point, MD, USA |
| PMH2 |
ESTABLISHING THE
EXPECTED RATE OF COGNITIVE DECLINE IN ALZHEIMER’S DISEASE?
Caro JJ1, Ward A1, Kelley H1, Ishak K2, Raggio G1, Robinson K3,
Molloy W4, 1Caro Research Institute, Concord, MA, USA; 2Caro Research
Institute, Dorval, QC, Canada; 3Janssen-Ortho Inc, Toronto, ON, Canada;
4McMaster University, Hamilton, ON, Canada |
| PMH3 |
ANTIPSYCHOTIC
AGENTS AND THE RISK OF DEVELOPING DIABETES
Caro JJ1, Ward A1, Levinton C1, Robinson K2, 1Caro Research
Institute, Concord, MA, USA; 2Janssen-Ortho Inc, Toronto, ON, Canada
|
| PMH4 |
SUPPLEMENTAL
ANALYSIS OF THE QUETIAPINE EXPERIENCE WITH SAFETY AND TOLERABILITY
(QUEST) STUDY
White R1, Simons WR2, Yu E1, 1AstraZeneca, Wilmington, DE, USA;
2Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA |
| PMH5 |
EFFICACY OF NURSE
TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN
PRIMARY CARE
Hunkeler EM1, Meresman JF2, Heargreaves WA3, 1Kaiser Permanente,
Oakland, CA, USA; 2Kaiser Permanente, Northern California, Santa Clara,
CA, USA; 3University of California, San Francisco, San Francisco, CA, USA |
| PMH6 |
RISK OF DIABETES
FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS
Zhao Z, Loosbrock DL, Eli Lilly and Company, Indianapolis, IN, USA |
| PMH7 |
OUTCOMES AND
COST OF TREATMENT WITH RISPERIDONE VERSUS OLANZAPINE AMONG PATIENTS WITH
CHRONIC SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS
Vera-Llonch M1, Oster G1, Delea T1, Rupnow M2, Grogg A2, 1Policy
Analysis Inc, Brookline, MA, USA; 2Janssen Pharmaceutica Products, L.P,
Titusville, NJ, USA |
|
Economic Outcomes
Presentations |
| PMH8 |
ONE YEAR
HOSPITALIZATION RATES IN PATIENTS WITH SCHIZOPHRENIA DURING LONG-TERM
TREATMENT WITH LONG-ACTING RISPERIDONE
Chue PS1, Devos E2, Duchesne IY3, Leal AR2, Mehnert A3,
1University of Alberta, Edmonton, Alberta, Canada; 2SGS Biopharma SA,
Wavre, Belgium; 3Janssen Pharmaceutica NV, Beerse, Belgium |
| PMH9 |
THE DIRECT AND
INDIRECT ECONOMIC COSTS OF PSYCHOTIC DISORDERS TO BOTH PATIENTS AND
CAREGIVERS
Simons WR1, White R2, Bassi R1, 1Global Health Economics &
Outcomes Research, Inc, Summit, NJ, USA; 2AstraZeneca, Wilmington, DE,
USA |
| PMH10 |
THE BURDEN OF
DEPRESSION IN CANADA
Desjardins B1, Laurier C2, 1University of Montreal, Faculty of
Pharmacy, Merck Frosst Canada Ltd, Kirkland, QC, Canada; 2University of
Montreal, Montreal, QC, Canada |
| PMH11 |
A SWEDISH
PHARMACOECONOMIC EVALUATION OF ESCITALOPRAM, A NEW SSRI: COMPARISON OF
COST-EFFECTIVENESS BETWEEN ESCITALOPRAM, CITALOPRAM, FLUOXETINE AND
VENLAFAXINE
François C1, Henriksson F2, Toumi M1, Kornfeld A1, 1Lundbeck SA,
Paris, France; 2Stockholm School of Economics, Stockholm, Sweden |
| PMH12 |
EMPLOYMENT-RELATED COSTS OF INFORMAL CAREGIVING FOR ALZHEIMER'S DISEASE
PATIENTS: EFFECTS OD RIVASTIGMINE TREATMENT
Gianfrancesco FD1, Chang S2, Wang RH1, 1HECON Associates, Inc,
Montgomery Village, MD, USA; 2Novartis Pharmaceutical Corporation, East
Hanover, NJ, USA |
| PMH13 |
IMPACT OF ANXIETY
ON ABSENTEEISM: ESTIMATES FROM THE 1997 MEDICAL EXPENDITURE PANEL SURVEY
Graff JS1, Taylor TN2, McBurney CR1, 1University of Michigan/
Pfizer Pharmaceuticals, Ann Arbor, MI, USA; 2Pfizer Inc, Ann Arbor, MI,
USA |
| PMH14 |
HEALTH CARE
EXPENDITURES OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND POST
TRAUMATIC STRESS DISORDER
Crystal-Peters J, Chang S, Long S, The MEDSTAT Group, Washington,
DC, USA |
| PMH15 |
PREVALENCE AND
COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CANADIAN CLAIMS DATABASE
Gilsenan AW1, Hopkins JS1, Sherrill BH1, Corey-Lisle PK2, Longo
CJ3, Raskin J3, 1RTI Health Solutions, Research Triangle Park, NC, USA;
2Eli Lilly and Company, Indianapolis, IN, USA; 3Eli Lilly Canada,
Scarborough, ON, Canada |
| PMH16 |
PREVALENCE AND
COSTS OF ACCIDENTS AMONG ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
PATIENTS
Swensen A1, Birnbaum H2, Ben-Hamadi R2, Greenberg P2, Cremieux
PY2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis
Group/Economics, Cambridge, MA, USA |
| PMH17 |
ECONOMICS OF
PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC IN OLDER PSYCHOTIC
PATIENTS AND IN PATIENTS WITH BIPOLAR DISORDER
White R1, Simons WR2, Bassi R2, 1AstraZeneca, Wilmington, DE, USA;
2Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA |
| PMH18 |
UTILIZATION AND
COST OF RESOURCES IN BIPOLAR PATIENTS RECEIVING ATYPICAL ANTIPSYCHOTICS
Meletiche DM1, Bolge SC2, Lasser R1, 1Janssen Pharmaceutica,
Titusville, NJ, USA; 2Consumer Health Sciences, Princeton, NJ, USA |
| PMH19 |
USING A
COMMUNITY SAMPLE TO DERIVE UTILITY VALUES OF SCHIZOPHRENIA TREATMENT
OUTCOMES FROM A TIME TRADE-OFF METHODOLOGY
Adams J1, Davey P1, Jackson D1, Croker V2, Aristides M3, Mullen
K2, Montgomery W2, 1Medical Technology Assessment Group, Chatswood West,
NSW, Australia; 2Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia;
3Medical Technology Assessment Group, London, UK |
| PMH20 |
WITHDRAWN |
| PMH21 |
INPATIENT
MEDICATION UTILIZATION AND COSTS OF RISPERIDONE, OLANZAPINE AND
QUETIAPINE: A RETROSPECTIVE CHART ABSTRACTION STUDY
Neighbors D1, Irish W1, Lopez R1, Degen K2, Swann A3, Grogg A4,
Myrie L1, Bell T1, Young AL1, Girts T4, Pottharst R1, 1RTI Health
Solutions, Research Triangle Park, NC, USA; 2Middlesex Hospital,
Middletown, CT, USA; 3The University of Texas Health Science Center at
Houston, Houston, TX, USA; 4Janssen Pharmaceutica, Titusville, NJ, USA |
| PMH22 |
ECONOMIC
OUTCOMES ASSOCIATED WITH OLANZAPINE VERSUS DIVALPROEX TREATMENT FOR ACUTE
MANIA: RESULTS FROM A RANDOMIZED CLINICAL TRIAL
Zhu B1, Baker R1, Altshuler L2, Zarate C3, Ketter T4, Lage M5,
Tunis S1, Shi L1, Tohen M1, 1Lilly Research Laboratories, Indianapolis,
IN, USA; 2UCLA Neuropsychiatric Institute and Hospital, Los Angeles, CA,
USA; 3National Institute of Mental Health, Bethesda, MD, USA; 4Stanford
University, Stanford, CA, USA; 5HealthMetrics Outcomes Research, Groton
Long Point, CT, USA |
| PMH23 |
THE COST
CONSEQUENCES OF CONTINUED TREATMENT-RESISTANCE IN DEPRESSION
Ozminkowski RJ1, Russell JM2, Crown WH3, Hawkins K1, Orsini L3,
Finkelstein S4, Berndt E4, 1The MEDSTAT Group, Inc, Ann Arbor, MI, USA;
2Cyberonics, Inc, Houston, TX, USA; 3The MEDSTAT Group, Cambridge, MA,
USA; 4Massachusetts Institute of Technology, Cambridge, MA, USA |
| PMH24 |
MODELING THE
ECONOMIC IMPACT OF GALANTAMINE TREATMENT IN PATIENTS WITH ALZHEIMER’S
DISEASE IN DIFFERENT HEALTH CARE SYSTEMS
Caro J1, Salas M1, Ward A1, Getsios D2, Migliaccio-Walle K1,
Garfield F1, 1Caro Research Institute, Concord, MA, USA; 2Caro Research
Institute, Dorval, QC, Canada |
| PMH25 |
COST IMPACT OF
DEPOT DOSAGE FORMS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS
Kraljevic I1, MacKeigan L1, Einarson T1, Remington G2, 1Faculty of
Pharmacy, University of Toronto, Toronto, ON, Canada; 2Centre for
Addiction and Mental Health, Toronto, ON, Canada |
| PMH26 |
A COMPARISON OF
RISPERIDONE AND OLANZAPINE MENTAL HEALTH COSTS FOR MANAGED CARE PATIENTS
WITH SCHIZOPHRENIA
Gianfrancesco F1, Durkin M2, Mahmoud R2, Grogg A2, Ruey-Hua W1,
1HECON Associates, Inc, Rockville, MD, USA; 2Janssen Pharmaceutica,
Titusville, NJ, USA |
| PMH27 |
SCHIZOPHRENIA
CARE AND ASSESSMENT PROGRAM (SCAP): THE IMPACT OF CLINICAL AND FUNCTIONAL
CHARACTERISTICS AND ANTIPSYCHOTIC MEDICATION TREATMENT ON OUTPATIENT AND
INPATIENT PSYCHIATRIC UTILIZATION
Russo P1, Palmer LA1, Vasey J2, 1The MEDSTAT Group, Inc,
Washington, DC, USA; 2The Pennsylvania State University, State College,
PA, USA |
| PMH28 |
IS DONEPEZIL
COST-EFFECTIVE IN THE TREATMENT OF ALZHEIMER’S DISEASE (AD)?
Sobolewski M1, Kuzniar J2, Splawinski J3, Marc M2, 1University of
Technology, Rzeszow, Poland; 2District Hospital No2, Rzeszow, Poland;
3Independent Centre for Economic and Pharmaceutical Research, Warsaw,
Poland |
|
Quality of Life Presentations |
| PMH29 |
THE EFFECTS OF
PANAX GINSENG ON QUALITY OF LIFE: A PILOT STUDY
Reddy P, Ellis J, University of Connecticut, Storrs, CT, USA |
| PMH30 |
INFLUENCE OF
CAREGIVING ON HEALTH STATUS OF DEMENTIA CAREGIVERS
Mulchandani D, Nayak RA, St. John's University, Jamaica, NY, USA |
| PMH31 |
CATEGORICAL
RESPONSE DEFINES TREATMENT EFFECTIVENESS OF OLANZAPINE VERSUS RISPERIDONE
IN THE IMPROVEMENT OF NEGATIVE SYMPTOMS AND QUALITY OF LIFE IN
SCHIZOPHRENIA
Kinon BJ1, Zhao Z2, 1Lilly Research Lab, Indianapolis, IN, USA;
2Eli Lilly and Company, Indianapolis, IN, USA |
| PMH32 |
THE IMPACT OF
DULOXETINE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ON THE QUALITY
OF LIFE IN DEPRESSION SCALE
Robinson RL, Obenchain RL, Croghan TW, Eli Lilly and Company,
Indianapolis, IN, USA |
| PMH33 |
QUALITY OF LIFE
IN SCHIZOPHRENIA: THE RELATIONSHIP BETWEEN PARTICIPANT SELF-REPORT AND
CLINICAL ASSESSMENT
Russo P1, Smith MW2, 1The MEDSTAT Group, Inc, Washington, DC, USA;
2VA Palo Alto Health Care System, Menlo Park, CA, USA |
| PMH34 |
PSYCHOMETRIC
EVALUATION OF THE MODIFIED STRAIN IN NURSING CARE ASSESSMENT SCALE
Ciesla G1, Frank L1, Kleinman L1, Brodaty H2, Rupnow M3, 1MEDTAP
International, Bethesda, MD, USA; 2University of New South Wales, Sydney,
Australia; 3Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA
|
|
Health Policy Presentations |
| PMH35 |
LABOR SUPPLY OF
POOR RESIDENTS IN METROPOLITAN MIAMI: THE ROLE OF DEPRESSION AND THE
CO-MORBID EFFECTS OF DRUG USE
Alexandre PK, French M, University of Miami, Miami, FL, USA |
| PMH36 |
IMPACT OF PRIMARY
PAYER TYPE ON ACCESS TO ANTIDEPRESSANT PHARMACOTHERAPY AMONG PATIENTS
DIAGNOSED WITH DEPRESSION
Hou X, Washington State University, Spokane, WA, USA |
| PMH37 |
WITHDRAWN |
| PMH38 |
CLINICAL
COMPARABILITY OF SCHIZOPHRENIA PATIENTS SERVED AT TWO PUBLIC SETTINGS:
VETERANS AFFAIRS (VA) AND NON-VA MEDICAID
Ascher-Svanum H1, Zhu B1, Stensland MD2, 1Eli Lilly and Company,
Indianapolis, IN, USA; 2Ohio University, Athens, OH, USA |
| PMH39 |
BASELINE
COMPARISON OF PATIENTS WITH SCHIZOPHRENIA USING OLANZAPINE, RISPERIDONE
AND TYPICAL ANTIPSYCHOTICS IN CALIFORNIA MEDICAID PROGRAM
Mulani P1, Gibson PJ2, McCombs J1, 1University of Southern
California, Los Angeles, CA, USA; 2Eli Lilly and Company, Indianapolis,
IN, USA |
| PMH40 |
THE IMPACT OF
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR PATIENTS IN THE CALIFORNIA
MEDICAID PROGRAM
Sterling KL, McCombs J, University of Southern California, Los
Angeles, CA, USA |
| PMH41 |
REDUCTION IN
LONG-ACTING BENZODIAZEPINE THERAPY AND ASSOCIATED FRACTURES IN ELDERLY
MEDICAID PATIENTS
Dodd MA, Shah BM, Gupchup GV, Anderson JR, The University of New
Mexico, Albuquerque, NM, USA |
| PMH42 |
FROM CONVENTIONAL
ANTIPSYCHOTICS TO ATYPICALS AND BACK: DYNAMIC PROCESSES IN THE DIFFUSION
OF NEW MEDICATIONS
Leslie DL, Rosenheck R, Yale University School of Medicine, West
Haven, CT, USA |
| PMH43 |
THE IMPACT OF A
FORMULARY EXPANSION TO INCLUDE ADDITION OF SECOND-GENERATION
ANTIPSYCHOTIC MEDICATIONS ON THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA
Mulani P, McCombs J, University of Southern California, Los
Angeles, CA, USA |
| PMH44 |
SURVEY AND STATED
PREFERENCE TECHNIQUES FOR ESTIMATING THE DEMAND FOR ALCOHOLISM
MEDICATIONS
Mark TL1, Bransberger P2, Kranzler HR3, 1The Medstat Group,
Washington, DC, USA; 2Westat, Rockville, MD, USA; 3University of
Connecticut School of Medicine, Farmington, CT, USA |
| PMH45 |
THE EFFECT OF
SCHIZOPHRENIA SYMPTOMS ON EMPLOYMENT OUTCOMES
Clark TJ, Harris SD, University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA |
| PMH46 |
MEDICATION
TREATMENT PATTERNS FOLLOWING THE INITIATION OF OLANZAPINE VERSUS
RISPERIDONE IN A NATURALISTIC SETTING
Zhao Z1, Lage MJ2, Tunis SL1, 1Eli Lilly and Company,
Indianapolis, IN, USA; 2HealthMetrics Outcomes Research, L.L.C, Groton
Long Point, CT, USA |
|
EAR, EYE & SKIN DISEASES/DISORDERS |
|
Clinical Outcomes
Presentations |
| PES1 |
QUANTIFYING
POTENTIALLY INAPPROPRIATE OPHTHALMIC BETA-BLOCKER USE IN THE MANAGEMENT
OF GLAUCOMA
Spooner JJ1, Barron JJ1, Ikeda LI2, Cockerham T3, Waugh WJ3,
Mozaffari E2, 1Health Core, Inc, Newark, DE, USA; 2Pharmacia Corp,
Peapack, NJ, USA; 3WellPoint Pharmacy Management, West Hills, CA, USA |
|
Economic Outcomes
Presentations |
| PES2 |
A
DECISION-ANALYTIC MODEL TO COMPARE THE COST OF METHYL AMINOLEVULINATE
PHOTODYNAMIC THERAPY WITH STANDARD TREATMENTS IN THE UK FOR
DIFFICULT-TO-TREAT BASAL CELL CARCINOMA AND ACTINIC KERATOSIS
Aristides M1, Tilden D1, Robinson P1, Weston A2, Davey P2,
Aldridge G2, 1Medical Technology Assessment Group, London, UK; 2Medical
Technology Assessment Group, Chatswood West, NSW, Australia |
| PES3 |
TOPICAL
CORITCOSTEROID AND PHYSICIAN VISIT UTILIZATION AND COSTS IN PATIENTS WITH
ATOPIC DERMATITIS
Kahler KH1, Pinkston P1, Freimark N2, 1Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA; 2Lakewood, NJ, USA |
| PES4 |
INFORMAL
CAREGIVERS COSTS IN THE ELDERLY US POPULATION: A MULTIVARIATE REGRESSION
MODEL OF THE VISUALLY IMPAIRED VERSUS UNIMPAIRED
Shih YCT1, Lustig SP2, 1MEDTAP International Inc, Bethesda, MD,
USA; 2Pfizer Inc, Groton, CT, USA |
| PES5 |
COST ANALYSIS OF
ISOTRETINOIN FOR SEVERE RECALCITRANT NODULAR ACNE
Neary M1, Peters JC2, Smith MW2, Hong J1, Ellis CN3, 1Hoffman La
Roche, Nutley, NJ, USA; 2Medstat Group Inc, Washington, DC, USA;
3University of Michigan Medical School, Ann Arbor, MI, USA |
| PES6 |
COST
EFFECTIVENESS OF PHOTODYNAMIC THERAPY (PDT) WITH VERTEPORFIN IN THE UK
Smith DH1, Fenn P2, Drummond M3, 1Kaiser Permanente Center for
Health Research, Portland, OR, USA; 2Nottingham University, Nottingham,
UK; 3Innovus Research (UK) Ltd. and University of York, Heslington, York,
UK |
| PES7 |
ECONOMIC
EVALUATION OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR PREDOMINANTLY
CLASSIC, SUBFOVEAL CNV SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Lees M1, Davey P1, Aldridge G1, Schulz M1, Aristides M2, 1Medical
Technology Assessment Group, Chatswood West, NSW, Australia; 2Medical
Technology Assessment Group, London, UK |
|
Quality of Life
Presentations |
| PES8 |
THE PATIENTS’
PERCEPTION OF THEIR PSORIASIS AND ITS TREATMENT THROUGH A DIARY
Taieb C, Myon E, PharmacoEconomics Programs, bioMérieux-Pierre
Fabre, Boulogne Billancourt, France |
| PES9 |
PSORIASIS AND
EVERYDAY LIFE: FIRST RESULTS
Taieb C, Myon E, PharmacoEconomics Programs, bioMérieux-Pierre
Fabre, Boulogne Billancourt, France |
| PES10 |
THE PSORIASIS
MANAGEMENT DURATION INDUCED DIFFERENCES IN THE DISABILTY’S REPERCUSSION
Taieb C, Myon E, PharmacoEconomics Programs, bioMérieux-Pierre
Fabre, Boulogne Billancourt, France |
| PES11 |
FUNCTIONAL
LIMITATIONS IN THE US ELDERLY POPULATION WITH VARYING LEVELS OF VISUAL
IMPAIRMENT
Lustig SP1, Shih YCT2, Prasad M2, 1Pfizer Inc, Groton, CT, USA;
2MEDTAP International Inc, Bethesda, MD, USA |
|
Health Policy Presentations |
| PES12 |
ANTIHISTAMINE
UTILIZATION AND COSTS IN PATIENTS WITH ATOPIC DERMATITIS
Kahler KH1, Pinkston P1, Freimark N2, 1Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA; 2non-affiliated, Lakewood, NJ, USA |
|
GASTROINTESTINAL DISEASES/DISORDERS |
|
Clinical Outcomes
Presentations |
| PGI1 |
EFFECTIVENESS OF
MEDICAL INTERVENTIONS IN PATIENTS WITH SYMPTOMS OF GERD – A SYSTEMATIC
REVIEW
Edwards S1, Wahlqvist P2, 1AstraZeneca UK Ltd, Hertfordshire, UK;
2AstraZeneca R&D Mölndal, Mölndal, Sweden |
| PGI2 |
THERAPEUTIC
COMPARABILITY OF PROTON PUMP INHIBITORS
von Scheele B, Sherrill B, Richter A, Devlin P, RTI Health
Solutions, Research Triangle Park, NC, USA |
|
Economics Outcomes
Presentations |
| PGI3 |
IMPACT OF PROTON
PUMP INHIBITOR UTILIZATION PATTERNS ON GASTROESOPHAGEAL REFLUX
DISEASE-RELATED COSTS
Hall JA1, Dodd SL2, Durkin M2, Sloan S2, 1Ingenix Pharmaceutical
Services, Eden Prairie, MN, USA; 2Janssen Pharmaceutica, Titusville, NJ,
USA |
| PGI4 |
WITHDRAWN |
| PGI5 |
COST-EFFECTIVENESS OF IV PPI'S IN THE TREATMENT OF NON-VARICEAL UPPER GI
BLEEDING FOLLOWING URGENT ENDOSCOPY
Herba K1, Barkun A1, Kennedy WA2, Fallone CA1, RUGBE Investigators
A1, 1McGill University Health Centre, Montreal, QC, Canada; 2University
of Montreal, Montreal, QC, Canada |
| PGI6 |
EFFECT OF
POSTOPERATIVE ILEUS ON LENGTH OF STAY IN COLECTOMY
Sarawate C, Dalal M, University of Illinois at Chicago, Chicago,
IL, USA |
| PGI7 |
ECONOMIC OUTCOMES
OF EMPLOYER BENEFICIARIES TREATED FOR IRRITABLE BOWEL SYNDROME (IBS)
Leong SA1, Barghout V2, Birnbaum HG1, Ben-Hamadi R1, Thibeault C1,
Frech F2, Ofman J3, 1Analysis Group/Economics, Cambridge, MA, USA;
2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;
3Cedars-Sinai/Zynx Health Inc, Los Angeles, CA, USA |
| PGI8 |
A COST ANALYSIS
OF DIAGNOSTIC AND TREATMENT STRATEGIES IN PATIENTS WITH SYMPTOMS OF
POUCHITIS
Shermock KM, Shen B, Lashner BA, Achkar JP, The Cleveland Clinic
Foundation, Cleveland, OH, USA |
| PGI9 |
THE
COST-EFFECTIVENESS OF INTRAVENOUS PROTON PUMP INHIBITOR CONTINUOUS
INFUSION (IV PPI) ADMINISTERED PRIOR TO ENDOSCOPY IN THE TREATMENT OF
PATIENTS WITH NON-VARICEAL UPPER GI BLEEDING
Barkun A1, Herba K1, Kennedy WA2, Fallone CA1, RUGBE Investigators
A1, 1McGill University Health Centre, Montreal, QC, Canada; 2University
of Montreal, Montreal, QC, Canada |
| PGI10 |
PHARMACY
DISPENSING PATTERNS, COST AND HEALTHCARE UTILIZATION: A STUDY OF
LANSOPRAZOLE
Johnson ML, Beyth R, Houston Center for Quality of Care and
Utilization Studies, Houston, TX, USA |
|
Quality of Life Presentations |
| PGI11 |
EFFECT OF
RABEPRAZOLE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS
REPORTING INEFFECTIVE RELIEF WITH PRIOR OMEPRAZOLE OR LANSOPRAZOLE
THERAPY
Girts TK, Siddique RM, Jokubaitis LA, Janssen Pharmaceutica Inc.,
Titusville, NJ, USA |
| PGI12 |
FACTOR STRUCTURE
AND FURTHER VALIDATION OF THE GASTROESOPHAGEAL REFLUX DISEASE (GERD)
SYMPTOM ASSESSMENT SCALE
Damiano A1, Siddique R2, Xu X1, Imeokparia A1, 1Covance Health
Economics and Outcomes Services Inc, Gaithersburg, MD, USA; 2Janssen
Pharmaceutica Inc, Titusville, NJ, USA |
|
Health Policy
Presentations |
| PGI13 |
USE OF
NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN PATIENTS AT HIGH RISK FOR
GASTROINTESTINAL SIDE EFFECTS IN A VETERANS AFFAIRS MEDICAL CENTER
Harris CL, Raisch DW, VA Cooperative Studies Program,
Albuquerque, NM, USA |
| PGI14 |
ASSESSMENT OF USE
OF THE VETERANS AFFAIRS' CRITERIA FOR NONSTEROIDAL ANTI-INFLAMMATORY
AGENTS
Harris CL, Raisch DW, VA Cooperative Studies Program,
Albuquerque, NM, USA |
|
INFECTION |
|
Clinical Outcomes
Presentations |
| PIN1 |
THE EFFECT OF
ANTIBIOTIC USE ON RETURN VISITS FOR ACUTE RESPIRATORY TRACT INFECTIONS
Fedorowicz F, Gardella P, Rubin S, Share D, Blue Cross Blue Shield
of Michigan, Detroit, MI, USA |
| PIN2 |
RETROSPECTIVE
ANALYSIS OF IMIPENEM/CILASTIN VERSUS PIPRACILLIN/TAZOBACTAM IN TREATMENT
OF INFECTED NEUTROPENIC PATIENTS
Egan TF1, McGhan WF2, 1Kennedy Health System and the University of
Sciences in Philadelphia, Stratford, NJ, USA; 2The University of the
Sciences in Philadelphia, Philadelphia, PA, USA |
|
Economic Outcomes
Presentations |
| PIN3 |
COST-EFFECTIVENESS OF VACCINE DEVELOPMENT AND ENVIRONMENTAL CONTROL
AGAINST DENGUE IN SOUTHEAST ASIA
Suaya JA1, Shepard DS1, Halstead S2, 1Brandeis University,
Waltham, MA, USA; 2Rockefeller Foundation, Rockville, MD, USA |
| PIN4 |
ECONOMIC IMPACT
OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ON HEALTHCARE RESOURCE
UTILIZATION AND COSTS IN THE UNITED STATES
Paramore C1, Ciuryla V2, Ciesla G1, Liu Z2, 1MEDTAP International,
Bethesda, MD, USA; 2Wyeth-Ayerst Research, Philadelphia, PA, USA |
| PIN5 |
COST-EFFECTIVENESS OF VACCINATING ADULT CLOSE CONTACTS WITH BOOSTRIX®
Kornfield TB1, Botteman MF1, Pashos C2, 1Abt Associates Clinical
Trials, Bethesda, MD, USA; 2Abt Associates Clinical Trials, Cambridge,
MA, USA |
| PIN6 |
DIRECT MEDICAL
COSTS OF MANAGING AN EPISODE OF RESPIRATORY SYNCYTIAL VIRUS (RSV)
COMMUNITY ACQUIRED PNEUMONIA (CAP) IN U.S. ADULTS
O'Brien J, Patrick A, Duran P, Klittich W, Lee K, Caro J, Caro
Research Institute, Concord, MA, USA |
| PIN7 |
EVALUATION OF THE
COST-EFFECTIVENESS OF AZITHROMYCIN VERSUS AMOXICILLIN, AMOXICILLIN/CLAVULANATE,
AND CLARITHROMYCIN FOR THE TREATMENT OF ACUTE SINUSITIS IN A LARGE
MANAGED CARE DATABASE
Harnett J1, Wilson J1, Cheng R2, 1Pfizer, Inc, New York, NY, USA;
2Protocare Sciences Inc, Santa Monica, CA, USA |
| PIN8 |
INCIDENCE AND
RELATED HEALTHCARE RESOURCE USE OF RESPIRATORY SYNCYTIAL VIRUS (RSV)
INFECTION IN A HIGH-RISK ADULT POPULATION: A CLAIMS DATABASE ANALYSIS
Iloeje UH1, Wu W2, Wu Y1, 1Bristol Myers Squibb Company,
Wallingford, CT, USA; 2Bristol Myers Squibb Company, Princeton, NJ, USA |
| PIN9 |
LONG-TERM
ECONOMIC CONSEQUENCES OF ORGAN DYSFUNCTION FOLLOWING HOSPITAL DISCHARGE
OF SEPSIS PATIENTS
Roberts CS, Chang L, Bakst AW, Mera RM, GlaxoSmithKline,
Collegeville, PA, USA |
| PIN10 |
COST-UTILITY OF
SELECTIVE BUPRENORPHINE SUBSTITUTION FOR METHADONE MAINTENANCE IN
PREVENTING HIV TRANSMISSION
Wall MJ1, Pollack HA2, 1University of Michigan and Pfizer Inc, Ann
Arbor, MI, USA; 2University of Michigan, Ann Arbor, MI, USA |
| PIN11 |
INITIAL
ANTIMICROBIAL THERAPY AND OUTCOMES IN PATIENTS HOSPITALIZED WITH
COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Onesirosan PT, Gutierrez B, Gaylord-Miles B, Hatch V, Premier,
Inc, Charlotte, NC, USA |
| PIN12 |
COSTS OF
TREATMENT FOR AMBULATORY LOWER RESPIRATORY TRACT INFECTION IN QUEBEC
SENIORS
Kennedy WA, Laurier C, Paré M, Philibert L,
University of Montreal, Montreal, QC, Canada |
| PIN13 |
THE IMPACT OF
ANTIBIOTIC SELECTION ON TREATMENT OUTCOMES FOR ACUTE OTITIS MEDIA
Ayyar Krishnan A, Christensen DB, University of North Carolina,
Chapel Hill, NC, USA |
| PIN14 |
HEALTH RESOURCE
UTILIZATION IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
Ahn J1, Mullins CD1, Shaya FT1, Merchant S2, Corcoran G2, Church
D2, 1University of Maryland, Baltimore, MD, USA; 2Bayer Pharmaceutical
Corporation, West Haven, CT, USA |
| PIN15 |
PREFERENCES AND
WILLINGNESS-TO-PAY FOR HEALTH STATES PREVENTED BY PNEUMOCOCCAL CONJUGATE
VACCINE
Prosser LA1, O'Brien MA1, Ray GT2, Santoli JM3, Lieu TA1, 1Harvard
Medical School and Harvard Pilgrim Health Care, Boston, MA, USA; 2Kaiser
Permanente, Oakland, CA, USA; 3Centers for Disease Control and
Prevention, Atlanta, GA, USA |
| PIN16 |
AN ECONOMIC
ASSESSMENT OF THE IMPACT OF ESCHERICHIA COLI RESISTANCE TO
TRIMETHOPRIM-SULFAMETHOXAZOLE IN THE TREATMENT OF URINARY TRACT INFECTION
Siefert R1, DeRouin D2, 1Siefert and Associates, Ventura, CA, USA;
2Greater Newport Physicians, Newport Beach, CA, USA |
|
Quality of Life
Presentations |
| PIN17 |
PRELIMINARY
RESULTS OF A U.S.-BASED STUDY TO VALIDATE THE ACUTE BRONCHITIS SYMPTOM
SEVERITY SCALE
Leidy NK1, Margolis MK1, Merchant S2, Gondek K2, Li-McLeod J2,
Kisken A2, Choudhri S2, Church D2, 1MEDTAP International, Bethesda, MD,
USA; 2Bayer Pharmaceutical Corporation, West Haven, CT, USA |
| PIN18 |
THE ASSOCIATION
BETWEEN HEALTH RELATED QUALITY OF LIFE AND ADHERENCE TO THERAPY IN
HEPATITIS C
Green J1, Wintfeld N1, Barker C2, Revicki D3, Bernstein D4,
1Hoffman LaRoche Inc, Nutley, NJ, USA; 2MEDTAP, Seattle, WA, USA; 3MEDTAP
International, Inc, Bethesda, MD, USA; 4North Shore University Hospital,
Manhasset, NY, USA |
| PIN19 |
PRESCRIBING
DECISIONS IN A UTILITY MODEL
Shaya FT1, Mullins CD1, Ahn J1, Merchant S2, Corcoran G2, Church
D2, 1University of Maryland, Baltimore, MD, USA; 2Bayer Pharmaceutical
Corporation, West Haven, CT, USA |
|
Health Policy
Presentations |
| PIN20 |
PHYSICIAN
PRESCRIBING PATTERNS FOR PEDIATRIC OTITIS MEDIA IN AMBULATORY PATIENTS
Rahman AM1, Feldhaus J2, Lawrence L2, Rappaport H2, 1St. John's
University, Jamaica, NY, USA; 2University of Louisiana at Monroe, Monroe,
LA, USA |
| PIN21 |
SECOND-LINE
THERAPY FOR OUTPATIENT TREATMENT FOR COMMUNITY-ACQUIRED PNEUMONIA
Singer ME, Jaffe DH, Case Western Reserve University, Cleveland,
OH, USA |
| PIN22 |
PATIENT TREATMENT
ACCORDING TO PRACTICE GUIDELINES IN COMMUNITY HOSPITALS COMPARED TO
TEACHING HOSPITALS IN THE COMMUNITY-ACQUIRED PNEUMONIA (CAP) PROJECT
Chaikledkaew U1, Hopefl A2, Goad JA1, Kamath TV3, Johnson KA1,
1University of Southern California, Los Angeles, CA, USA; 2AmeriNet, St.
Louis, MO, USA; 3Bristol-Myers Squibb, Princeton, NJ, USA |
| PIN23 |
THE IMPACT OF
PHYSICIAN REPORTED RISK FACTORS ON HOSPITALIZATION RATES FOR INFANTS ON
PALIVIZUMAB THERAPY
Marks AS, Berger J, Slezak J, Johnson KE, Caremark, Inc,
Northbrook, IL, USA |
| PIN24 |
WHAT IS THE VALUE
OF WARD SUPPLY DATA FOR MONITORING ANTIBIOTIC USE IN HOSPITAL?
Ofori BD1, Davey PG2, 1Ninewells Hospital and Medical
School, Dundee, UK; 2University of Dundee, Dundee, UK |
|
MEN’S & WOMEN’S HEALTH |
|
Clinical Outcomes
Presentations |
| PMW1 |
LIFE EXPECTANCY
PREDICTION OF HRT FOR PRIMARY PREVENTION STRATEGIES IN POST-MENOPAUSAL
WOMEN
Perreault S, Levinton C, Montreal University, Montreal, QC, Canada |
|
Economic Outcomes
Presentations |
| PMW2 |
ECONOMIC ANALYSIS
OF SILDENAFIL CITRATE ADD-ON TO TREAT SSRI-INDUCED ERECTILE DYSFUNCTION
Nurnberg HG1, Duttagupta S2, 1University of New Mexico,
Albuquerque, NM, USA; 2Pfizer Pharmaceuticals Group, Pfizer Inc, New
York, NY, USA |
| PMW3 |
COVERAGE OF
SILDENAFIL CITRATE BY EMPLOYERS AND HEALTH PLANS: LOWER THAN EXPECTED
PHARMACY BENEFIT COSTS AND ADDITIONAL HEALTH BENEFITS
Lehman G1, Duttagupta S2, 1National Business Coalition on Health,
Washington, DC, USA; 2Pfizer Pharmaceuticals Group, Pfizer Inc, New York,
NY, USA |
| PMW4 |
DEVELOPING A
BETTER UNDERSTANDING OF COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY
(HRT): A COMPREHENSIVE REVIEW OF ECONOMIC ANALYSIS FROM 1980 TO 2001
Shah NP1, Botteman MF2, Gold KF2, Brandman J3, 1Abt Associates
Clinical Trials, Cambridge, MA, USA; 2Abt Associates Clinical Trials,
Bethesda, MD, USA; 3Pfizer Inc, New York, NY, USA |
| PMW5 |
COST-EFFECTIVENESS ANALYSIS OF CURRENTLY MARKETED LONG-TERM
CONTRACEPTIVES
Knight K, Reyes E, Wallace J, Chiou CF, Wade S, Borenstein
J,
Cedars-Sinai Health System, Zynx Health Incorporated, Beverly Hills, CA,
USA |
| PMW6 |
COST
EFFECTIVENESS MODELING COMPARING RECOMBINANT FSH WITH URINARY FSH FOR
OVARIAN STIMULATION – A MULTINATIONAL EVALUATION
Beresniak A1, Daya S2, Duru G3, Auray JP3, 1Serono International
SA, Geneva, Switzerland; 2McMaster University, Hamilton, Ontario, Canada;
3Université Claude Bernard Lyon, Villeurbanne, France |
| PMW7 |
IDENTIFYING
PATIENT AND HOSPITAL-RELATED PREDICTORS OF MATERNITY LENGTH OF STAY AND
TOTAL INPATIENT CHARGES FOR OBSTETRICAL DELIVERIES IN A NATIONAL SAMPLE
Mody R, Amonkar M, Kamat S, West Virginia University, Morgantown,
WV, USA |
|
Quality of Life
Presentations |
| PMW8 |
BENIGN PROSTATIC
HYPERPLASIA: RECOGNITION OF THE CONSEQUENCES OF THE PATHOLOGY FOR THE
SPOUSE
Taieb C, Cohen A, Myon E, PharmacoEconomics Programs, bioMérieux-Pierre
Fabre, Boulogne Billancourt, France |
| PMW9 |
BENIGN PROSTATIC
HYPERPLASIA: CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE- RISK OF
SOMNOLENCE
Taieb C1, Abbadie S2, Myon E1, 1PharmacoEconomics Programs,
bioMérieux-Pierre Fabre, Boulogne Billancourt, France; 2Economic Affairs,
bioMérieux-Pierre Fabre, Boulogne Billancourt, France |
|
NEUROLOGICAL/PAIN DISORDERS |
|
Economic Outcomes
Presentations |
| PNP1 |
SOCIO-ECONOMIC
IMPACT OF MIGRAINE IN FRANCE IN 2000
Pradalier A1, Auray JP2, Duru G2, Chazot G3, Dartigues JF4, Henry
P5, Lanteri-Minet M6, Lucas C7, El Hasnaoui A8, Gaudin AF8, 1Hopital
Louis Mourier, Colombes, France; 2Université Claude Bernard,
Lyon, France; 3Hopital Cardio Vasculaire et Neurologique, Bron, France;
4Université Bordeaux II, Bordeaux, France; 5Hopital Pellegrin, Bordeaux,
France; 6CHU de Nice, Nice, France; 7Hospital Roger Salengro, Lille,
France; 8Laboratoire Glaxo Wellcome, Marly le Roi, France |
| PNP2 |
COST-EFFECTIVENESS OF RAPID MRI VERSUS LUMBAR X-RAY AS THE INITIAL
INVESTIGATION FOR PRIMARY CARE PATIENTS WITH LOW BACK PAIN: A RANDOMIZED
CONTROLLED TRIAL
Hollingworth W1, Jarvik J2, Gray DT2, Deyo RA2, Martin BI2,
Sullivan SD2, 1University of Cambridge, Cambridge, UK; 2University of
Washington, Seattle, WA, USA |
| PNP3 |
SOCIETAL
PERSPECTIVE, USING CLINICAL TRIAL OUTCOMES
Kwon SY, Hartzema AG, University of Florida, Gainesville, FL, USA |
| PNP4 |
PRESCRIBING
PATTERNS OF LONG-ACTING OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN IN THE
VETERANS ADMINISTRATION SYSTEM
Shermock KM1, Mchaourab A2, Secic M3, Schein J4, Durkin M4,
1Shermock Health Outcomes Research, Bay Village, OH, USA; 2Cleveland
Veterans Administration Hospital, Cleveland, OH, USA; 3Secic Statistical
Consulting, Cleveland, OH, USA; 4Janssen Pharmaceutica, Titusville, NJ,
USA |
|
Quality of Life
Presentations |
| PNP5 |
A CONJOINT
EXERCISE WITH PHYSICIANS, PATIENTS AND MCO FORMULARY MANAGERS: DRUG
CHOICE TRADEOFFS IN TREATMENT OF MIGRAINE HEADACHE
Lee AJ, Lee AM, Lee Analytics, Lowell, MA, USA |
| PNP6 |
WHAT IS IMPACT OF
INSOMNIA ON MEDICAL DISORDERS, QUALITY OF LIFE AND ABSENTEEISM? A STUDY
IN A FRENCH WORKING POPULATION
Jasso Mosqueda JG1, Philip P2, Leger D3, Maria Antonieta QS4,
Taillard J2, Niedhammer I5, Bioulac B2, Gerard D6, Chicoye A1,
1Annie Chicoye Economics, Neuilly/Seine France; 2Clinique du Sommeil, Chu
Bordeaux, Bordeaux, France; 3Centre de Sommeil Hôtel Dieu de Paris,
Paris, France; 4Laboratoire du sommeil,
Chu Paris-Ouest, Garches, France; 5Inserm U 88 Hnsm, Saint Maurice,
France; 6Sanofi-Synthélabo, Meudon la Foret, France |
|
Health Policy
Presentations |
| PNP7 |
THE MIGRAINE IN
FRANCE IN 2000
Henry P1, Auray JP2, Duru G2, Chazot G3, Dartigues JF4, Lanteri-Minet M5,
Lucas C6, Pradalier A7, El Hasnaoui A8, Gaudin AF8, 1Hopital
Pellegrin, Bordeaux, France; 2Université Claude Bernard, Lyon, France;
3Hopital Cardio Vasculaire et Neurologique, Bron, France; 4Université
Bordeaux II, Bordeaux, France; 5CHU de Nice, Nice, France; 6Hospital
Roger Salengro, Lille, France; 7Hopital Louis Mourier, Colombes, France;
8Laboratoire Glaxo Wellcome, Marly le Roi, France |
| PNP8 |
MULTIPLE
SCLEROSIS: COMPLIANCE TO COPAXONE® THERAPY
Marks AS, Johnson KE, Caremark, Inc, Northbrook, IL, USA |
| PNP9 |
TRIPTAN
UTILIZATION PATTERNS IN A MANAGED CARE POPULATION
Etemad LR1, Yu W2, Johnson KA1, 1University of Southern
California, Los Angeles, CA, USA; 2WellPoint Pharmacy Management, West
Hills, CA, USA |
| PNP10 |
THE STATE OF
ANTI-EPILEPTIC DRUG PRESCRIBING: RESEARCH AND PRACTICE
Pugh MJ1, Knoefel J2, Mandell A3, Charbonneau A1, Berlowitz D1,
1Center for Health Quality, Outcomes and Economic Research, VA, Bedford,
MA, USA; 2VA New Mexico, Albuquerque, NM, USA; 3ENRM VAMC, Bedford, MA,
USA |
|
URINARY/KIDNEY DISEASE/DISORDERS |
|
Clinical Outcomes
Presentations |
| PUK1 |
A COMPARISON OF
PD AND HD PATIENT SURVIVAL ALLOWING FOR SWITCHES FROM PD TO HD
Weijnen T, de Charro F, Erasmus University Rotterdam, Rotterdam,
Netherlands |
| PUK2 |
UTILIZATION
PATTERNS ASSOCIATED WITH TOLTERODINE IMMEDIATE RELEASE VERSUS OXYBUTYNIN
IN THE MANAGEMENT OF URINARY INCONTINENCE (UI)
Boccuzzi SJ1, Le TK1, Wogen J1, Williamson T2, 1The Institute for
Effectiveness Research, LLC, Bridgewater, NJ, USA; 2Pharmacia
Corporation, Peapack, NJ, USA |
|
Economic Outcomes
Presentations |
| PUK3 |
COST
EFFECTIVENESS OF INTENSIVE BEHAVIORAL MANAGEMENT VERSUS DDAVP IN PRIMARY
NOCTURNAL ENURESIS
Egan TF1, McGhan WF2, 1Kennedy Health System and the University of
Sciences in Philadelphia, Stratford, NJ, USA; 2Philadelphia College of
Pharmacy, Philadelphia, PA, USA |
| PUK4 |
AN ECONOMIC MODEL
OF OVERACTIVE BLADDER IN NORWAY
Bentkover J1, Bachleda M2, Kulseng-Hansen S3, Corey R4, Kurth H1,
1Innovative Health Solutions, Brookline, MA, USA; 2Pharmacia Corporation,
Peapack, NJ, USA; 3Baerum Sykehus, Gjettum, Norway; 4University of the
Sciences in Philadelphia, Pharmacia Corporation, Peapack, NJ, USA |
| PUK5 |
INCIDENCE AND
COST ASSOCIATED WITH PHARMACOLOGICAL TREATMENT FOR EMPLOYEES DIAGNOSED
WITH URINARY AND OVERACTIVE BLADDER DISORDERS
Muchmore L1, Williamson TE2, Gardner H1, 1Options and Choices,
Cheyenne, WY, USA; 2Pharmacia, Peapack, NJ, USA |
| PUK6 |
A BUDGET IMPACT
ANALYSIS OF EARLY REFERRAL TO A NEPHROLOGIST FOR ELDERLY MEDICARE
PATIENTS WITH
END-STAGE RENAL DISEASE
Shih YCT1, Guo AM2, Prasad M1, Just PM2, 1MEDTAP International
Inc, Bethesda, MD, USA; 2Baxter Healthcare Corporation, Deerfield, IL,
USA |
|
Quality of Life
Presentations |
| PUK7 |
DEVELOPMENT OF
THE SYMPTOM FREQUENCY AND BOTHERSOMENESS SCALE FOR STRESS URINARY
INCONTINENCE (SFB-SUI)
Garvart S1, Bowman L2, Buesching D2, Patrick D3, Martin M4, 1Eli
Lilly and Company, Windlesham, UK; 2Eli Lilly and Company, Indianapolis,
IN, USA; 3University of Washington, Seattle, WA, USA; 4Health Research
Associates, Seattle, WA, USA |
| PUK8 |
VALIDATION OF THE
PERCEPTION OF BLADDER CONDITION MEASURE IN OVERACTIVE BLADDER
Coyne K, Matza LS, MEDTAP International, Inc, Bethesda, MD, USA |
| PUK9 |
VALIDATION OF THE
URGENCY PERCEPTION SCALE
Cardozo L1, Coyne KS2, Versi E3, 1Kings College Hospital, London,
UK; 2MEDTAP International, Bethesda, MD, USA; 3Pharmacia Corporation,
Peapack, NJ, USA |
| PUK10 |
ASSESSING PATIENT
SATISFACTION IN A DIALYSIS Cafarelli M1, Chapman MM1, Brown RH2, Zager
PG2, Meyer KB1, 1New England Medical Center, Boston, MA, USA; 2Dialysis
Clinic, Inc, Albuquerque, NM, USA |
| PUK11 |
EFFECTS OF
LONG-TERM TOLTERODINE TREATMENT ON PHYSICAL AND SYMPTOM ASPECTS OF
HEALTH-RELATED QUALITY OF LIFE IN OVERACTIVE BLADDER PATIENTS
Okano GJ, Pleil AM2, Reese PR1, Kelleher CJ3, 1Strategic Outcomes
Services of CareScience, Research Triangle Park, NC, USA; 2Pharmacia
Limited, High Wycombe, Bucks, UK; 3Guys and St. Thomas’ NHS Trust,
London, UK |
| PUK12 |
HOW RESPONSIVE IS
THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q) TO CHANGES IN URGENCY,
FREQUENCY, AND INCONTINENCE?
Tomera KM1, Coyne K2, Matza LS2, Corey R2, 1Alaska Clinical
Research Center, Anchorage, AK, USA; 2MEDTAP International, Inc,
Bethesda, MD, USA; 3University of the Sciences in Philadelphia,
PharmaciaCorporation, Peapack, NJ, USA |
|
